Clinical Trial Update: Low Dose Melphalan and Bortezomib for AML and High-Risk MDS [NA]

View source ↗

Summary

Clinical trial of low-dose melphalan and bortezomib for acute myeloid leukemia and high-risk myelodysplastic syndromes has completed with results posted in 2013…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Myelodysplastic Syndromes

Drugs mentioned

• Bortezomib (bortezomib)
• melphalan (low-dose) (melphalan)

Snippet

Sponsor: Dartmouth-Hitchcock Medical Center | Conditions: Acute Myelogenous Leukemia, Myelodysplastic Syndromes | NA | Status: COMPLETED | Results posted: 2013-07-22